A nationwide Swedish study found that moderate antipsychotic doses were most effective at preventing psychotic relapse after cannabis-induced psychosis — higher doses didn't add benefit and likely increased side effects.
Psychiatrists treating cannabis-induced psychosis, patients prescribed antipsychotics after a psychotic episode, pharmacologists studying dose-response optimization.
What the researchers found
Using linked Swedish health registers, researchers identified all individuals with a first diagnosis of cannabis-induced psychosis and conducted a dose-response analysis of oral antipsychotic medications.
The analysis modeled antipsychotic exposure as time-dependent across three dose categories (low: <0.6 DDD, moderate: 0.6–<1.4 DDD, high: ≥1.4 DDD) using within-individual comparisons — meaning each person served as their own control across different exposure periods.
The primary outcome was hospitalization for any psychotic episode (schizophrenia-spectrum disorder or substance-induced psychosis). The results showed a dose-response curve that plateaued at moderate doses: low doses provided some protection, moderate doses were most effective, and high doses did not add further benefit.
The within-individual design is particularly strong because it eliminates confounding from differences between patients (genetics, severity, comorbidities) — it only compares how the same person fares at different dose levels.
Why it matters
Cannabis-induced psychosis carries a high conversion rate to chronic psychotic illness (RTHC-00251 found ~34% convert to schizophrenia). Antipsychotics can prevent relapse, but they carry dose-related side effects including weight gain, metabolic syndrome, and movement disorders. This study provides the first real-world dose optimization data, suggesting clinicians can achieve maximum benefit at moderate doses without the added burden of high-dose treatment.
The numbers in context
Three dose categories: <0.6 DDD (low), 0.6–<1.4 DDD (moderate), ≥1.4 DDD (high). Medications analyzed: aripiprazole, clozapine, risperidone, olanzapine, quetiapine, polytherapy, and others. Outcome: hospitalization for schizophrenia-spectrum or substance-induced psychosis. Moderate doses showed optimal protection; high doses showed no additional benefit.
How the study worked
Nationwide cohort study using linked Swedish administrative and healthcare registers. All first diagnoses of cannabis-induced psychosis (ICD-10 F12.5) identified. Antipsychotic exposure modeled as time-dependent using validated PRE2DUP method. Dose-response analyzed across three DDD categories. Within-individual stratified Cox regression. Primary outcome: hospitalization for psychotic episode.
Who was studied
N=1,772 individuals aged 16-64 years with first-time cannabis-induced psychosis in Sweden from 2006 to 2021
What this study cannot tell us
Register-based study — medication exposure is estimated from dispensing records, not confirmed adherence. Cannabis use during follow-up was not measured and may confound results. The Swedish healthcare system may not generalize to other settings. Within-individual design requires that patients contribute periods at different dose levels, which may introduce selection effects.
How to read the evidence
Nationwide cohort study with within-individual design — one of the strongest observational designs available, leveraging Sweden's comprehensive health registers.
When this study was published
Published in 2026 using Swedish register data, providing real-world evidence on antipsychotic dosing that complements clinical trial data.
The bigger picture
This connects directly to the psychosis conversion meta-analysis (RTHC-00251) by addressing what to do about that ~34% conversion rate. If moderate-dose antipsychotics can reduce relapse without the full side-effect burden of high doses, that changes the risk-benefit calculation for treating cannabis-induced psychosis — potentially making clinicians and patients more willing to use preventive medication during the critical post-episode period.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Does the optimal dose differ by specific antipsychotic (e.g., aripiprazole vs. olanzapine)? How long should antipsychotic treatment continue after cannabis-induced psychosis? Would combining moderate-dose antipsychotics with cannabis cessation support further reduce relapse rates?
Read the original research
Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.
Psychiatry research, 358, 116966
Psychiatry Research is a reputable journal focusing on mental health and psychiatric studies.
Citation
Mustonen, Antti; Niemelä, Solja; Denissoff, Alexander; Forti, Marta Di; Tanskanen, Antti; Mittendorfer-Rutz, Ellenor; Tiihonen, Jari; Taipale, Heidi. (2026). Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.. Psychiatry research, 358, 116966. https://doi.org/10.1016/j.psychres.2026.116966
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)